MAP2K7 and neoplasm: Paired tumor biopsies in patients with CRC harboring BRAF-V600E mutations and treated with triple-pronged therapy targeting BRAF, EGFR, and MEK showed that an increase in T-cell infiltration occurred after blockade of the MAPK pathway via BRAF inhibition [82].